OmniAb, Inc. (OABI) Earnings Call Transcript & Summary
August 8, 2024
Earnings Call Speaker Segments
Kurt Gustafson
executiveThanks, operator, and good afternoon to all of you. I'm Kurt Gustafson, OmniAb's Chief Financial Officer, and I appreciate everyone joining us for our conference call on second quarter 2024 financial results. Slides have been prepared to go along with today's remarks, and you can find them in the Investors section of our website, omniab.com. Before we get started, as outlined on Slide 2, I want to remind those listening that statements made on this call will contain forward-looking statements under the meaning of the federal securities laws. Such forward-looking statements carry risks and uncertainties that might cause actual results to differ materially from any results anticipated. The cautionary statements in today's press release and our SEC filings qualify these forward-looking statements. Importantly, this conference call includes time-sensitive information that is accurate only as of the date of the live broadcast today, August 8, 2024. Except as required by law, OmniAb assumes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. With me on the call today is Matt Foehr, OmniAb's President and CEO. During today's call, Matt and I will provide highlights on the company's operations, partner and technology updates and our recent financial results. Once our prepared remarks conclude, we'll open the call to questions. And with that, let me turn the call over to Matt.
Matt Foehr
executiveThanks, Kurt. Good afternoon, everybody, and I appreciate you all being with us today for our Q2 conference call. I'll take over the presentation this afternoon here on Slide #4. Over the course of the quarter, we kept expanding our business by bringing in new partnerships. With the speed at which new deals are coming in and a book of business that keeps growing, there's a chance this year ends up being our strongest ever when it comes to new partners and licenses; at the same time, our current partners keep moving their programs forward in the clinic, which makes our pipeline stronger this year and beyond. We're generating growth in the business through solid execution, and we're accomplishing that with an efficient operating structure and a business model that's highly scalable. We plan to build more visibility for our platform via publications and by moving our technologies forward. Our scientists just published a significant peer-reviewed paper in the Journal of Immunology about our OmnidAb, a single-domain antibody technology, which we launched last November and which is now fueling a rising number of new partner programs. And I'd also point out that in the second quarter, we successfully showed the efficient multi-site deployability of a next-generation exploration instrument across our labs. I bring up the exploration platform here because it could drive extra efficiencies for our partner programs and further expand our position as an industry leader in speed, throughput, reliability, and ease of use for antibody discovery screening activities. We stay committed to continuously improving our technology so we can meet the evolving and broadening needs of our partners and keep a leading market position. I'm proud of what our team has achieved and feel confident in our ability to execute our strategy so we can maximize value for all of our stakeholders; now, turning to Slide #5, I'll begin reviewing some of our business metrics for the quarter. We ended Q2 with 83 active partners. That figure includes 2 new platform license agreements we signed during the quarter; those are with DAAN Bio and Topaz Therapeutics. Notably, Topaz is a company focused on radio conjugates, and they are the first of what we expect will be multiple partners focused on this space. I'd also note that we mentioned in our earnings release, which we issued this afternoon, that we expanded our existing successful discovery relationship with HanAll Biopharma, and also recently closed new deals with 92Bio and the Memorial Sloan Kettering Cancer Center. As I said, with the speed at which new deals are coming in and our growing book of business, there's a chance this year ends up being our strongest ever in new partner adds. Now, on Slide #6, you'll see that our partnership base has grown by 30% over the last 2 years. And these numbers, I'd note, are net of attrition. The growth we've seen in our partner count comes mainly from people validating what our platform can do, plus launches of new technologies, and more recently from stepping up our business development work; turning to the following slide, Slide #7, the geographic breakdown of our partners is shown there, tied to where each partner has its headquarters. That said, I'd point out that a lot of our partners run development programs on a worldwide basis. Most of our partners sit in the U.S., with Europe and Asia represented in roughly equal measure; and across the last year, we've grown our business development footprint beyond the U.S., which we anticipate will bring about more diversity in our partner base. Active programs at quarter end, net of attrition, appear on Slide 8. Active programs rose to $333 million, which works out to a net gain of 6 programs versus Q1. In Q2, 1 program went from discovery into preclinical, 1 went from preclinical into Phase 1, and a third went from Phase 1 into Phase 3. Our partners keep aligning and reprioritizing their therapeutic programs and pipelines as part of ordinary business; within our small molecule ion channel programs, GSK realigned parts of its portfolio during Q2 and chose to stop its work on the small molecule Nav1.1 sodium channel modulator program, which targeted rare epilepsies. GSK is still moving forward a separate preclinical stage program with us in neurological diseases; and after the second quarter closed, Roche chose to hand back its rights to a small molecule program aimed at Kv7.2, following one more internal portfolio review on their side. We remain engaged with Roche on 2 other small molecule ion channel programs that could potentially treat CNS disorders. In line with our business model and the contractual terms of those deals, the Kv7.2 and Nav1.1 small molecule programs are assets we're able to repartner with other parties in the CNS space. Now on Slide 9, what you see is growth in our partners' preclinical and later-stage programs, some of which we believe may matter for near-term and mid-term value generation in our pipeline; the count of these programs has grown 39% across the last 2 years, and right now we've arrived at 50 programs in total at these stages. Our pipeline is strong and expanding, and we're eager to see our partners make progress as they push programs toward later stages of clinical development and on to the market. As shown here now on Slide #10, we had 32 active clinical programs and approved products as of June 30. Teva entered the clinic during the quarter with TEV-56278, an OmniChicken-derived PD1 with IL-2 fusion. On their earnings call last week, Teva publicly called attention to ex vivo data for this program. The results indicated promising antitumor T-cell activity, and they mentioned their belief that this program could pave the way for further combination treatment strategies. Given our conversations with partners—and with 1 now completed—our expectation remains that 4 to 6 novel OmniAb-derived antibodies will enter clinical development during this year. On the next slide, Slide #11, you can see the extensive and expanding array of formats our antibodies are able to accommodate. And while this list is already fairly comprehensive, as we continue innovating on the platform and broadening our partner network, we keep witnessing growth in the count of new formats. Though this slide is highly technical, it genuinely offers a good depiction of how broad and adaptable our platform is. The latest new format to reach the clinical stage is the ATTENUKINE multi-specific with Teva, which I referenced earlier and which began clinical testing in Q2; you can see it on the lower section of the center panel here. Moving to Slide #12, I want to point out several important recent and Q2 partner developments. Genmab reported initial findings from the Phase 2 study assessing acasunlimab both as a monotherapy and combined with pembro in patients who have PD-L1-positive metastatic non-small cell lung cancer. Information from this continuing Phase 2 research supports their anticipated pivotal Phase 3 trial, which is slated to begin before 2024 comes to a close.
Matt Foehr
executiveCStone just shared news that sugemalimab, when paired with chemo, won European approval as an initial-line option for metastatic non-small cell lung cancer — a disease area that ranks among the biggest cancer indications and also sits among the top causes of cancer mortality. Beyond that, CStone revealed it has formed a strategic commercial partnership with Ewopharma. Per the terms of that deal, Ewopharma holds commercial rights to sugemalimab across Switzerland plus the 18 Central Eastern European Countries. Cessation offered preliminary findings from its Phase 1a first-in-human trial of CSX-1004, an investigational antibody designed to prevent fentanyl-related overdose, showing CSX-1004 to be safe and well-tolerated under the tested conditions. Furthermore, and this matters, the exposure data pointed toward efficacy when it comes to blocking fentanyl-induced respiratory depression too. Moving forward, Cessation intends to run a Phase 2 proof-of-concept study. I brought up Teva's efforts earlier, and their clinical start also gets a mention here on this slide; and finally, Tallac revealed FDA clearance of its IND application for ALTA-002, a SIRP-alpha targeting toll-like receptor agonist antibody conjugate aimed at patients with advanced solid tumors. Looking at Slide #13 here, we anticipate many catalysts arriving across the rest of the year and into 2025. What you see is a subset of publicly disclosed events, spanning a blend of clinical readouts, clinical starts and regulatory events. And we remain thrilled by the progress our partners keep reporting; and my final slide, Slide #14, offers an up-to-date snapshot of overall milestone potential across our pipeline; and it also flags those 50 preclinical and later-stage programs in our pipeline that I pointed to earlier as near-term and mid-term value drivers. On the right side of this slide, you can see that those 50 programs at preclinical-stage and beyond carry more than $550 million in potential milestones to OmniAb; and on the whole, our active antibody programs hold over $3 billion in potential milestones, while the remaining active small molecule ion channel programs with Roche and GSK carry roughly $700 million in remaining milestones. With that, I'll hand the call back to Kurt so he can walk through our second quarter financial results. Kurt?
Kurt Gustafson
executiveThanks, Matt. I'll give you a quick rundown of our financial results for the second quarter, and after that, we'll open it up for questions. If you turn to Slide 16, you'll find our income statement covering Q2 2024 alongside the comparable period a year earlier. Revenue totaled $7.6 million for the quarter, up against $6.9 million in the same quarter last year. That top line came in right where we anticipated, aside from service revenue running higher. Matt brought up that GSK halted its small molecule ion channel program, and that event caused an extra $1.3 million of service revenue to be pulled forward beyond what we otherwise would have booked during the quarter. GSK had prepaid those service fees, so they sat as deferred revenue and were being amortized across the research term. When the program was discontinued, that amortization got accelerated, and most of it would otherwise have been taken into income across the coming 2 quarters. As I said earlier, we still anticipate milestone payments landing disproportionately in the back half of the year, based on what our partners have told us and the statements they've made; on the cost side, R&D expense came in roughly flat against the prior year. G&A came to $8 million, versus $8.7 million a year ago, and the drop largely reflects reduced share-based compensation along with non-recurring costs tied to our ERP system implementation that hit the prior year. Amortization of intangibles during Q2 ran above our recent pattern. That bump came from a $1.2 million impairment on assets tied to 2 legacy unpartnered Ab Initio programs. Beyond that, other operating income for the quarter reflected a $2.6 million decrease in contingent liabilities, mostly driven by changes in the ion channel programs. We carry CVR obligations from our Icagen acquisition that lapse in 2027, and we accrue those CVR liabilities according to our projections about hitting various milestones. Recent notices from GSK and Roche lowered our expected obligations on those CVRs, and that reduction got booked in other operating income here. Through the year so far, operating expenses have stayed fairly close to plan. That said, we now anticipate total operating expenses for 2024 coming in a touch below 2023's total. Now to Slide 17. This shows our balance sheet dated June 30, 2024. We closed Q2 holding $57.2 million in cash, and as we've noted previously, we expect the first half of '24 to burn more than the second half, in part because milestone revenue skews toward the back half and in part because of when certain operating expense cash payments landed in Q1. Since we remain near our original plans, our cash guidance is unchanged. With that, let's open the line for questions. Operator?
Michael Sonntag
analystHello. Michael here, filling in for Puneet. Nice work on the quarter. For my first question, I'd like to discuss the exploration platform a bit. You brought up a proof-of-concept study that was completed. I'm wondering whether you could explain how this distributed approach you're examining aligns with what you offer overall. Also, could you address the level of confidence regarding the IP, given that there's been some litigation in the microfluidics single cell area lately?
Matt Foehr
executiveSure, Michael, I appreciate the question. And yes, the exploration platform has clearly been part of our technology portfolio for a long time — it goes back to when we acquired it roughly 4 or 5 years ago. It's a high throughput B cell screening platform, and it also applies broadly to other fields. However, our main focus has been on B cell screening workflows. This platform has generated significant efficiencies across our business. In fact, some of our bigger partners have approached us asking about obtaining access to exploration instruments. As we've put money into that platform to boost throughput and speed, we've realized it's really a form of — it's something that generates considerable leverage for the business. You brought up the IP landscape; in our case, this is a microcapillary platform. So the manner in which the equipment operates is pretty distinctive. And beyond being highly efficient at screening, it leverages — it can be combined with deep learning and AI and other capabilities we've been working on for many years to truly enhance throughput. So we're enthusiastic about the exploration platform. It's something we've clearly invested in throughout the years and keep leveraging in numerous ways for our partners.
Michael Sonntag
analystAll right, excellent. Then I was wondering — when you talk with partners who are new or ones you already work with — whether you've picked up anything about how interested they are in discovery programs, especially since funding during the first half has been fairly solid. On top of that, there's plenty of discussion around the prioritization going on at large pharma companies. So I'd be interested to hear whatever perspective you can share on that.
Matt Foehr
executiveSure, Michael, I'm happy to speak to that, and Kurt can jump in if there's more to add. Right — clearly, if you follow this industry, you can see that big pharma keeps working through prioritization efforts, and that's to be expected. It's the kind of thing that occurs on a secular basis across the industry. Still, for us Q2 was very strong when it came to new programs getting started, and we truly have a wide range of partners. There's a blend of large pharma companies and startups, plus academic collaborations too. When I look at where things stand today versus roughly a year back, you notice that several of our more recent partners are very well capitalized. These startups have money behind them, strong VC backing, compelling biology, and ideas that stand apart, and they're approaching us so they can tap into our platform; we're certainly seeing that far more often than we did, let's say, a year or even 2 years ago. So overall, that's encouraging. And I'd say it sits alongside the prioritization efforts taking place at big pharma. Then again, in my view that's simply a normal feature of this industry.
Michael Sonntag
analystExcellent. Many thanks.
Chad Wiatrowski
analystHello everyone. Chad here, filling in for Steve Mah. If we examine the current programs, there's a fairly significant downstream milestone opportunity. With the cluster of partner catalysts expected over the next 18 months, what level of visibility do you actually have?
Kurt Gustafson
executiveYeah, I'd say our forecasts come from a mix of information that's public and information that's private. A number of our partners have publicly stated when they anticipate kicking off a Phase 2 or a Phase 3 program. So you can clearly watch for that. And in certain instances, partners have given us richer detail about what they intend to do. So I'd say our visibility might be slightly greater than what those outside the company have, thanks to some of the data we receive — though that data isn't flawless, and sometimes we learn that things shift, correct. A partner will say they plan to begin something during the upcoming quarter, and then that timeline slides. Still, beyond what's available publicly, we do receive some extra information.
Matt Foehr
executiveI'll just tack on a small point there too, Chad — broadly, once programs get into the clinic is the moment they tend to draw far more attention and become much more visible to investors. Take this quarter: TEV-56278 is a case in point, isn't it. That's a program that had essentially no public profile before it launched, and it was nice last week to see it being spotlighted on their earnings call. Still, from the public's standpoint, that program was likely flying under the radar. But by and large, when things move past preclinical and reach Phase 1, that's when outside observers begin to gain considerably more visibility into individual programs.
Chad Wiatrowski
analystGreat. And yes, one clear advantage of your model right now is that it works like a platform for sharing R&D. But when it comes to exploration, since most of the R&D money has already been spent, would you ever consider selling instruments straight to partners?
Matt Foehr
executiveYes. Look, Chad, that's a terrific question. I'd say it's something we would talk about — and we'd walk through those plans openly as they took shape. People have come to us wanting exploration instruments; we're aware it can be deployed. We're aware it has wide use. We're aware it generates efficiencies. So all of that, I believe, opens up optionality for the business and gives us things to consider going forward.
Chad Wiatrowski
analystThanks for the questions guys.
Kurt Gustafson
executiveThanks Chad.
Stephen Willey
analystYes. Good afternoon, everyone. Thank you for fielding the questions. I was simply curious about how the possible re-partnering of those CNS assets coming back to you from GSK and Roche ranks among your present priorities. Also, were these development candidates that had reached IND-enabling studies? Is that the correct way to view their development stage? And I know you said you keep co-ownership of the IP tied to the Glaxo small molecule, but does that hold true for the Roche asset too?
Matt Foehr
executiveYes. Steve, I appreciate the question. From a stage standpoint, I'd describe them as discovery plus preclinical, correct. I mean, particularly in that small molecule area, they're undergoing testing in animal models and similar work. So that's roughly how I'd frame the stage. We can now re-partner them. Once again, both of these sit in the CNS space. And that's definitely something we've accomplished before. If you examine our history, clearly, our central emphasis is technology innovation and development and licensing our technologies. Yet programs frequently emerge from our technology development, and we've successfully licensed individual assets previously. We currently have certain assets that are open for licensing, and we pursue that. So that's sort of a byproduct. Developing assets on our own isn't our plan. But we view these as excellent candidates for possible re-partnering. Interest is increasing in a few of these ion channel spaces. Clearly, we're more centered on the antibody side at this point, but there are people centered on small molecules too; so yes, I hope that provides you with a bit more color.
Stephen Willey
analystAll right. So perhaps if we take a step back to the macro picture briefly, I'm just a bit curious — clearly, you mentioned that certain reprioritization moves inside large pharmaceutical companies have a tendency to move in cycles. A big CRO came out yesterday, obviously, offering rather wary remarks regarding spending by big pharma specifically on the discovery side and outsourced work. Do those developments shape where you allocate your time from a business development standpoint?
Matt Foehr
executiveThat's an interesting question, Steve, and clearly, as I've mentioned, these cycles are something we observe. A great deal of our BD work, correct — perhaps I can respond to that in a couple of ways. Much of our business development activity is now — we're reaching out more and more ourselves, yet a substantial amount of inbound interest in our platform still arrives, which I believe speaks volumes as the platform keeps growing, as it gains further validation, as additional papers and peer-reviewed journal articles get published, all of which tends to draw inbound interest. We now have a good blend across our portfolio, with our 83 partners spanning large pharma companies, early-stage startups, and academic groups. So we hold a rather intriguing vantage point regarding the direction people are heading. Thus, the way I'd put it is that our relationships don't just shape the BD work we perform — they shape the innovation we pursue too. And I believe that fuels interest. One factor behind our ability to expand the business, in terms of both partners and programs net of attrition, is that people recognize we keep innovating, and that, I think, brings partners in as well. So our conversations clearly are — plenty of forward-looking dialogue happens with our partners, particularly the bigger ones; so — and they're thinking further downstream with a far more long-term discovery orientation, even when a company might view its current portfolio differently or shuffle its priorities.
Stephen Willey
analystMoving to the startup aspect, whenever you're working with those businesses at earlier stages, and maybe such businesses are actually getting built around assets found off your platform. What's your thinking on economic return when it involves something like acquiring a founder's equity position as opposed to attempting to maximize economics further downstream, or do you believe both can be achieved under one particular deal structure?
Matt Foehr
executiveYes, our belief is that both can indeed be achieved. Let me say, as is our habit of saying, NPVs guide us when structuring deals, yet every single deal differs, correct. Consequently, we take pride in crafting adaptable structures suited to us and our stakeholders, while also being suited to the partners. Things such as equity positions and similar arrangements are definitely something we're open to. Such a history certainly exists for me, and our past management team had it too; thus, those sorts of arrangements are something we welcome. Still, our partner mix does excite us. Recently, over the last few months, we brought in some quite thrilling startup firms possessing genuinely compelling concepts, innovative biology, management teams with a track record. So each of those elements helps shape our thinking while we're closing a deal with a partner, though multiple structure types remain something we'd consider. In a model such as ours, I believe there are numerous distinct methods for generating value.
Stephen Willey
analystOkay. Thanks for taking the questions.
Matt Foehr
executiveThanks Steve.
Conor McNamara
analystThanks, and good to get the questions in. I wanted to ask about 2025. The press release mentioned a big decline in cash use. What should we be thinking about in terms of where that revenue step-up is coming from? Does it mean royalties become a bigger contributor in 2025, or does the mix stay similar, with more milestones flowing through? Can you say anything about how we ought to frame that for 2025?
Kurt Gustafson
executiveSure, Conor, that breaks into two pieces. The first piece is the operating leverage I've mentioned before that's embedded in this business. We've essentially scaled the business to the size it needs to be, and our headcount is where it needs to be. As a result, aside from inflation, you really shouldn't expect any meaningful rise in operating expense. Actually, according to our most recent projections, operating expense for 2024 will come in lower than 2023. When it comes to what causes a meaningful reduction in cash burn, though, that depends on revenue, and specifically on milestone revenue. On royalties, we currently bring in royalties from a few products in China. We should point out that one of those programs, one of those compounds, was just approved in Europe. So something could materialize there. Still, our forecast for that shift really hinges on higher milestones. Consider those roughly 50 assets Matt referenced that are in preclinical or clinical stages right now. As each one advances to its next stage, milestones get triggered. That, in our view, is what will mainly drive it.
Conor McNamara
analystGreat. And by the way — I appreciate that. Regarding the disclosure of the absolute dollar amount, I believe this is the first occasion you've split it out by stage, correct? The $3 billion is broken out, so I think that's useful — have you presented that data previously?
Kurt Gustafson
executiveNo, this was the initial time we released that. So, thanks for catching it.
Conor McNamara
analystAll right, that's a big help. I appreciate the extra detail; very useful. Then, moving on quickly — regarding the European approval you brought up. Should we assume — I mean, will any royalty revenue come through from that during 2024, or is it a relatively minor opportunity in your view? Can that be put into numbers somehow?
Kurt Gustafson
executiveAt this point it's difficult to say. I mean, sugemalimab comes with a 3% royalty on sales globally. As things stand — CStone has stated they're seeking a partner for, as I'd put it, the EU. For Switzerland and Central Eastern Europe, a partner already exists in EwoPharma; that was announced; however, they don't actually — they won't be launching it on their own. A partner is being sought, and per their statement, updates would be coming shortly; so, Conor, I'm not sure, when it comes to — we'll simply need to wait and observe which partner they manage to secure. That said, my view is this could generate additional royalty revenue, though at present it isn't included in what we're projecting.
Conor McNamara
analystGood. Kurt, I appreciate you taking those questions. Thank you for that. Nice work on a strong quarter.
Kurt Gustafson
executiveAbsolutely. Thank you, Conor.
Matt Foehr
executiveOkay. Appreciate that, Conor. That appears to be the final inquiry, so I want to express my gratitude to all of you for joining us on this call today, as well as for the questions and the engagement. We're eager to continue sharing updates on how we're doing and to talk with you once more a few months from now. You'll be able to find us at a number of conferences that are coming up, among them the H.C. Wainwright Conference, which takes place in New York City next month, and we hope to see some of you there. So once again, thank you for the interest you've shown in OmniAb, and enjoy the rest of your day.
Operator
operatorEveryone, that wraps up today's conference call. We appreciate you taking part, and we ask that you kindly hang up your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.